


Ongoing Trials – status update



PORTEC-4a



Trial setting: Stage I-II endometrial cancer - high-intermediate risk

Study Design: Randomised trial of molecular profile-based versus standard recommendations for adjuvant radiotherapy

Sponsor(s): LUMC; **funding:** Dutch Cancer Society

Planned No. of patients: 500

Current accrual: 147

Other important information: Clinical Trials Ireland in set-up; ANZGOG and GINECO planning to participate (awaiting grant), NRG and CTC exploring participation



Inclusion criteria: FIGO 2009 – high intermediate risk

- Stage IA (with invasion), any age with grade 3
- Stage IB, grade 1-2 and age > 60
- Stage IB, grade 1-2 and LVSI+
- Stage IB, grade 3 without LVSI
- Stage II (microscopic), grade 1

Ongoing Trials – status update



PORTEC-4a





Pilot phase (n=50) endpoints:

- Logistics of molecular analysis (< 2 wks)
- Patient acceptance
- **Completed: 50 pts**



PORTEC-4a study endpoints (n=500):

- Vaginal control and RFS
- Pelvic and distant recurrence and OS
- Quality of life and freedom from symptoms
- Costs and use of health care resources
- **Current total: 147**

- Requirement to determine profile within 2 working weeks
- Participating groups: validation of molecular profile & logistics; dummy run procedure for brachytherapy
- **Satellite : Thursday Oct 18, 16:00-16:30 h, Seminar Room II**